{
  "nctrialId": "HC-1303",
  "title": "A Randomized Open-Label, Active-Controlled  Study of ALZ-309 (beta-amyloid antibody) in Patients With Osteoarthritis",
  "officialTitle": "A Randomized Open-Label, Active-Controlled  Study of ALZ-309 (beta-amyloid antibody) in Patients With Osteoarthritis",
  "sponsor": "Princess Margaret Cancer Centre",
  "indication": "Osteoarthritis",
  "phase": "Phase 2",
  "fileName": "HC-1303.json",
  "fileSize": 385466,
  "date": "2025-02-05",
  "completionDate": "2026-12-04",
  "drugName": "ALZ-309 (beta-amyloid antibody)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Withdrawn",
  "description": "This is a randomized open-label, active-controlled  study designed to evaluate the efficacy and safety of ALZ-309 (beta-amyloid antibody) in patients with Osteoarthritis. The study will enroll approximately 478 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 27-71 years\n- Confirmed diagnosis of Osteoarthritis\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment",
  "csr_id": "HC-1303"
}